Exelixis Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
70 / 1361
Position in country
1227 / 14179
Return on Assets, %
6.7
-40.3
Net income margin, %
17.8
-180
EBITDA margin, %
18.4
-168.2
Debt to Equity, %
0
3.2
Intangible assets and goodwill, %
2.1
0.2
Revenue CAGR 3Y, %
22.8
12.5
Total Equity change 1Y, %
-9.1
-9
Revenue Y, % chg
13.6
0
P/E
35.2
31
P/BV
3
1.8
P/S
3.7
10.3
EV/S
3.2
7.5
EV/EBITDA
30.1
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
18.3
131.1
Forward P/E
17.6
21.4
Expected dividend per share
0
0
Payout Ratio, %
0
0
Competitors
Ranks
-
Exelixis Inc
00%
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
6915.8
Ticker
EXEL.O
ISIN
US30161Q1040
IPO date
2000-04-11
Availability on Russian exchanges
Yes
Reporting for
2024-02-06
Date fact. publication of reports
2023-12-31
Company Description
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: